Frontier Diagnostics

Who are Frontier Diagnostics

Frontier Diagnostics are improving the survival rates of cancer patients and increasing their quality of life by using new revolutionary early detection techniques, Ai-driven tools, genomic insights, and precision medicine.

Frontier Diagnostics is developing a blood-based cancer diagnostic platform that enables clinicians to detect, understand, and monitor tumour behaviour using circulating tumour cells (CTCs). Suitable Investors can invest with exciting returns, and help the future of cancer care.

✔ Discounted Share Offer - £1.70 Price per share offer. £12.5m Valuation 

✔ £85–90bn - Global cancer diagnostics market 

✔ £9–10bn - Liquid biopsy diagnostics market today, projected to exceed £18bn over the next decade 

✔ The oncology diagnostics market is growing exponentially, driven by rising cancer incidence, demand for earlier insight, and increasing adoption of repeatable diagnostic approaches. 

✔ £8.1m Gross profit forecast by 2028 £17.8m by 2029. £30.4m by 2030. 

✔ Frontier is initially focused on breast cancer, where monitoring needs are well defined and clinical pathways are established.

EIS Benefits For Qualifying Investors Include

✔ HMRC EIS Approved with 30% Income Tax Relief 

✔ Capital gains tax deferral on gains reinvested into EIS Shares

✔ Inheritance tax relief after the qualifying holding period. 

✔ Loss relief against income or capital gains if the investment underperforms. 

Any person accessing the email or profile and considering potential investment opportunities featured on the email should make their own commercial assessment of an investment opportunity after seeking the advice of an appropriately authorised or regulated financial advisor. This email should not be construed as advice or a personal recommendation to any prospective investor.